Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OFA-CHU Nīmes (Opioid-Free Analgesia protocol by Centre Hospitalier Universitaire de Nīmes) is a multimodal analgesic combination therapy consisting of paracetamol, nefopam, tramadol, and ketamine. Developed for use in intensive care unit (ICU) settings, particularly for patients requiring mechanical ventilation, the protocol aims to provide effective pain management while minimizing or eliminating the requirement for potent opioids such as remifentanil. By utilizing drugs with distinct mechanisms of action—including cyclooxygenase inhibition (paracetamol), monoamine reuptake inhibition and ion channel modulation (nefopam), weak mu-opioid receptor agonism and monoamine reuptake inhibition (tramadol), and NMDA receptor antagonism (ketamine)—the protocol targets multiple pathways of pain signaling. This approach is intended to reduce opioid-associated complications such as respiratory depression, ileus, and hyperalgesia in critically ill patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paracetamol + Nefopam + Tramadol + Ketamine.